{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:19:29Z","timestamp":1771337969331,"version":"3.50.1"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Neuroendocrine tumors (NETs) are a group of biologically and clinically heterogeneous neoplasms arising from the diffuse neuroendocrine system. In the last few years, advances in our understanding of the biology of these tumors have translated into an expansion of treatment options for patients with NETs. Current treatment modalities include somatostatin analogs (SSAs), radiolabeled SSAs, targeted agents, cytotoxic drugs and liver-directed therapies for the management of metastatic disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Recent studies have expanded the role of SSAs in gastroenteropancreatic (GEP)-NETs, and everolimus has shown robust antitumor activity across a broad range of NETs of the lung and GEP tract. The radiolobeled SSA <jats:sup>177<\/jats:sup>Lu-DOTATATE has been investigated in a randomized phase III trial, and has demonstrated exceptional efficacy and tolerability in patients with progressive midgut NETs. The new serotonin inhibitor telotristat etiprate has shown significant activity in the palliation of symptoms of carcinoid syndrome, and its approval by regulatory authorities is expected soon.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The field of NETs has been transformed from one dominated by limited treatment options to one characterized by an increasing number of therapeutic agents and active clinical trials. Navigating the current therapeutic algorithm may be challenging, and requires an understanding both of the heterogeneity of NETs and of characteristics that are shared by NETs across tumor subtypes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000000299","type":"journal-article","created":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T13:29:37Z","timestamp":1462282177000},"page":"359-366","source":"Crossref","is-referenced-by-count":24,"title":["Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials"],"prefix":"10.1097","volume":"28","author":[{"given":"Mauro","family":"Cives","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heloisa P.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Strosberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230901","first-page":"749","article-title":"An update on gastroenteropancreatic neuroendocrine tumors","volume":"28","author":"Cives","year":"2014","journal-title":"Oncology (Williston Park)"},{"key":"R2-20230901","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35\u200a825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"R3-20230901","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/ERC-13-0125","article-title":"Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature","volume":"21","author":"Fraenkel","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"R4-20230901","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1200\/JCO.2014.60.2532","article-title":"Carcinoid and neuroendocrine tumors: building on success","volume":"33","author":"Kunz","year":"2015","journal-title":"J Clin Oncol"},{"key":"R5-20230901","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s40265-015-0397-7","article-title":"The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors","volume":"75","author":"Cives","year":"2015","journal-title":"Drugs"},{"key":"R6-20230901","doi-asserted-by":"crossref","first-page":"R173","DOI":"10.1530\/ERC-15-0413","article-title":"Predictive factors of response to mTOR inhibitors in neuroendocrine tumours","volume":"23","author":"Zatelli","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"R7-20230901","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"R8-20230901","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, nonfunctional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2015","journal-title":"Lancet"},{"key":"R9-20230901","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1294.001","article-title":"The \u201cnormal\u201d endocrine cell of the gut: changing concepts and new evidences","volume":"1014","author":"Rindi","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"R10-20230901","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(63)90951-6","article-title":"The classification of carcinoid tumours","volume":"1","author":"Williams","year":"1963","journal-title":"Lancet"},{"key":"R11-20230901","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.2011.35.1817","article-title":"Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors","volume":"29","author":"Strosberg","year":"2011","journal-title":"J Clin Oncol"},{"key":"R12-20230901","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1200\/JCO.2012.44.5924","article-title":"Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors","volume":"31","author":"Strosberg","year":"2013","journal-title":"J Clin Oncol"},{"key":"R13-20230901","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1530\/EJE-15-0968","article-title":"Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors","volume":"174","author":"Kamp","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"R14-20230901","first-page":"13","article-title":"Nomenclature and classification of neuroendocrine neoplasms of the digestive system","author":"Rindi","year":"2010","journal-title":"World Health Organization Classification of Tumors of the Digestive System"},{"key":"R15-20230901","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1158\/1078-0432.CCR-15-0548","article-title":"Well differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas","volume":"22","author":"Tang","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R16-20230901","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/PAS.0b013e3182417d36","article-title":"Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well differentiated pancreatic neuroendocrine tumors","volume":"36","author":"Yachida","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"R17-20230901","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.humpath.2015.08.006","article-title":"Molecular characteristics of colorectal neuroendocrine carcinoma; similarities with adenocarcinoma rather than neuroendocrine tumor","volume":"46","author":"Takizawa","year":"2015","journal-title":"Hum Pathol"},{"key":"R18-20230901","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1038\/ncomms4518","article-title":"Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids","volume":"5","author":"Fernandez-Cuesta","year":"2014","journal-title":"Nat Commun"},{"key":"R19-20230901","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"key":"R20-20230901","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/ng.2821","article-title":"Somatic mutation of CDKN1B in small intestine neuroendocrine tumors","volume":"45","author":"Francis","year":"2013","journal-title":"Nat Genet"},{"key":"R21-20230901","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1158\/1078-0432.CCR-15-0373","article-title":"Prognostic impact of novel molecular subtypes of small intestinal neuroendocrine tumor","volume":"22","author":"Karpathakis","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R22-20230901","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/2159-8290.CD-15-0068","article-title":"A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics","volume":"5","author":"Sadanandam","year":"2015","journal-title":"Cancer Discov"},{"key":"R23-20230901","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"O\u2019Toole","year":"2000","journal-title":"Cancer"},{"key":"R24-20230901","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1634\/theoncologist.2014-0120","article-title":"Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study","volume":"19","author":"Strosberg","year":"2014","journal-title":"Oncologist"},{"key":"R25-20230901","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","volume":"9","author":"Wolin","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"R26-20230901","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/ERC-14-0173","article-title":"Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide","volume":"21","author":"Kulke","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"R27-20230901","article-title":"Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy: the phase III TELESTAR clinical trial","author":"Kulke","journal-title":"2015 European Cancer Congress"},{"key":"R28-20230901","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"R29-20230901","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"R30-20230901","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177Lu\u2013DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"R31-20230901","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.hoc.2015.09.009","article-title":"Peptide receptor radionuclide therapy in the treatment of neuroendocrine tumors","volume":"30","author":"Kwekkebom","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"key":"R32-20230901","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1200\/jco.2016.34.4_suppl.194","article-title":"NETTER-1 phase III: progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate","volume":"34","author":"Strosberg","year":"2016","journal-title":"J Clin Oncol"},{"issue":"(S7)","key":"R33-20230901","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mds295","article-title":"Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Oberg","year":"2012","journal-title":"Ann Oncol"},{"key":"R34-20230901","first-page":"118","article-title":"ENETS 2016 consensus guidelines for the management of patients with digestive neuroendocrine tumors: an update","volume":"103","author":"O\u2019Toole","year":"2016","journal-title":"Neuroendocrinology"},{"key":"R35-20230901","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/02841860701441848","article-title":"Peptide receptor radionuclide therapy with radiolabeled somatostatin analogues in patients with somatostatin receptor positive tumors","volume":"46","author":"Van Essen","year":"2007","journal-title":"Acta Oncol"},{"key":"R36-20230901","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumors associated with carcinoid syndrome (RADIANT-2): a randomized, placebo-controlled, phase III study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"R37-20230901","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","article-title":"Activity of sunitinib in patients with advanced neuroendocrine tumors","volume":"26","author":"Kulke","year":"2008","journal-title":"J Clin Oncol"},{"key":"R38-20230901","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(15)70136-1","article-title":"Pazopanib and depot octreotide in advanced, well differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study","volume":"16","author":"Phan","year":"2015","journal-title":"Lancet Oncol"},{"key":"R39-20230901","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"R40-20230901","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2007.13.6374","article-title":"Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"R41-20230901","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/jco.2015.33.15_suppl.4004","article-title":"SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127)","volume":"33","author":"Yao","year":"2015","journal-title":"J Clin Oncol"},{"key":"R42-20230901","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1200\/JCO.2014.56.2082","article-title":"Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors","volume":"33","author":"Hobday","year":"2015","journal-title":"J Clin Oncol"},{"key":"R43-20230901","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/MPA.0000000000000255","article-title":"Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well differentiated neuroendocrine tumors","volume":"44","author":"Yao","year":"2015","journal-title":"Pancreas"},{"key":"R44-20230901","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000403785","article-title":"The role of chemotherapy in well differentiated gastroenteropancreatic neuroendocrine tumors","volume":"44","author":"Strosberg","year":"2015","journal-title":"Front Horm Res"},{"key":"R45-20230901","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.hoc.2015.09.010","article-title":"Hepatic-directed therapies in patients with neuroendocrine tumors","volume":"30","author":"Kennedy","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"key":"R46-20230901","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1093\/annonc\/mdr614","article-title":"A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors","volume":"23","author":"Strosberg","year":"2012","journal-title":"Ann Oncol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00001622-201607000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T06:22:25Z","timestamp":1693549345000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201607000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000299","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}